A dose range study on FK 037 in bacterial pneumonia

Rinzo Soejima, Yoshihito Niki, Niro Okimoto, Osamu Moriya, Hitoshi Nakano, Kenjiro Kikuchi, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Kazuki Konishi, Kazuo Obara, Masashi Tamura, Akira Watanabe, Hiroshi Takahashi, Shigeo Takizawa, Mikae Nakamura, Kohya Shiba, Osamu Sakai, Kazuhisa Okada, Hiroichi TanimotoKazuo Obara, Tetsuo Okamura, Kaoru Shimada, Yasuyuki Sano, Norihisa Akiyama, Yasuko Tanaka, Takashi Inamatsu, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Jingoro Shimada, Seiji Hori, Fumio Matsumoto, Takeo Imai, Kouji Yoshikawa, Shigeki Odagiri, Yoshihiro Hirai, Norio Kikuchi, Yasutoshi Suzuki, Osamu Sekine, Nobuki Aoki, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Toshinobu Yamamoto, Hidekazu Hanaki, Makoto Kawakami, Shinji Takeyama, Ikuji Usami, Hidekazu Kuroki, Fumio Miki, Nobuhiro Narita, Keiichi Mikasa, Masayoshi Sawaki, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yuji Sugimoto, Ikuo Matsumoto, Jiro Takahara, Jiro Fujita, Masaru Kamei, Yoshiro Sawae, Kaoru Okada, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Hozumi Yamada, Osamu Kato, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Sadahiro Asai, Naofumi Suyama, Jun Araki, Hideo Mashimoto, Rokushi Oka, Hidenori Sugiyama, Koichi Watanabe, Keizo Matsumoto, Hiroshi Watanabe, Akemi Ohmori, Moritoshi Akiyama, Yoshiaki Utsunomiya, Kazunori Oishi, Tsuyoshi Nagatake, Hirofumi Tanaka, Hidehiko Hirose, Masakazu Takasugi, Atsushi Saito, Jun Inatome, Hiroshi Fukuhara, Yuei Irabu, Keisuke Sunakawa

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

A dose range study on FK 037, a parenteral cephalosporin, was conducted in patients with bacterial pneumonia. 1) Patients with bacterial pneumonia were intravenously infused with FK 037 at a dose of 0.5 g (0.5 g group), 1.0 g (1.0 g group) or 2.0 g (2.0 g group), twice daily, for 14 days as a rule. Of 95 patients, 82 were assessed for the efficacy and clinical usefulness of the drug, and 93 patients for the safety of the drug. 2) The clinical efficacy rate was 85.2% (23/27) in the 0.5 g group, 90.0% (27/30) in the 1.0 g group and 92.0% (23/25) in the 2.0 g group. 3) In the bacteriological evaluation, the eradication rate was 91.7% (11/12) in the 0.5 g group, 85.7% (6/7) in the 1.0 g group and 90.9% (10/11) in the 2.0 g group. 4) As for side effects, diarrhea was observed in only 1 patient in the 1.0 g group. 5) Abnormal changes in laboratory tests were observed in 6 patients (19.4%) in the 0.5 g group, 11 patients (34.4%) in the 1.0 g group and 5 patients (17.9%) in the 2.0 g group. None of the abnormal laboratory findings was serious or associated with clinical symptoms. 6) Clinical usefulness rates were 81.5% (22/27), 86.7% (26/30) and 92.0% (23/25) in the 0.5 g, 1.0 g and 2.0 g group, respectively. We considered that a twice daily dose of 1.0 g of FK 037 is the appropiate clinical dosase for bacterial pneumonia.

Original languageEnglish
Pages (from-to)1143-1161
Number of pages19
JournalChemotherapy
Volume42
Issue number10
DOIs
Publication statusPublished - 1994

Keywords

  • FK 037

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A dose range study on FK 037 in bacterial pneumonia'. Together they form a unique fingerprint.

Cite this